EE200000152A - Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon - Google Patents

Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon

Info

Publication number
EE200000152A
EE200000152A EEP200000152A EEP200000152A EE200000152A EE 200000152 A EE200000152 A EE 200000152A EE P200000152 A EEP200000152 A EE P200000152A EE P200000152 A EEP200000152 A EE P200000152A EE 200000152 A EE200000152 A EE 200000152A
Authority
EE
Estonia
Prior art keywords
mcp
amino
pharmaceutical composition
host cell
expression vector
Prior art date
Application number
EEP200000152A
Other languages
English (en)
Estonian (et)
Inventor
Proost Paul
Struyf Sofie
Van Damme Jo
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200000152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200000152A publication Critical patent/EE200000152A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EEP200000152A 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon EE200000152A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (fr) 1997-09-29 1997-09-29 C-C chémokine tronquée à l'aminoterminus comme antagoniste de chémokines
EP97122471A EP0905240A1 (fr) 1997-09-29 1997-12-19 Amino-terminale tronquée C-C chemokin et d'un antagoniste chemokin
EP98104216A EP0905241A1 (fr) 1997-09-29 1998-03-10 Amino-terminale tronquée C-C chemokine et d'un antagoniste de chemokin
PCT/EP1998/006142 WO1999016876A1 (fr) 1997-09-29 1998-09-28 Mcp-2 tronque a acide amine terminal comme antagonistes de la chemokine

Publications (1)

Publication Number Publication Date
EE200000152A true EE200000152A (et) 2001-02-15

Family

ID=8227408

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200000152A EE200000152A (et) 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
EEP200000151A EE200000151A (et) 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP200000151A EE200000151A (et) 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon

Country Status (28)

Country Link
US (5) US6977071B2 (fr)
EP (6) EP0906954A1 (fr)
JP (2) JP4233214B2 (fr)
KR (2) KR100542934B1 (fr)
CN (3) CN1145693C (fr)
AR (2) AR013529A1 (fr)
AT (3) ATE368742T1 (fr)
AU (2) AU750606B2 (fr)
BG (2) BG64757B1 (fr)
BR (2) BR9812394A (fr)
CA (2) CA2305017A1 (fr)
CY (1) CY1110927T1 (fr)
CZ (2) CZ299478B6 (fr)
DE (3) DE69823218T2 (fr)
DK (3) DK1439231T3 (fr)
EA (2) EA003940B1 (fr)
EE (2) EE200000152A (fr)
ES (3) ES2215324T3 (fr)
HU (2) HU226468B1 (fr)
IL (2) IL135351A (fr)
NO (2) NO20001584D0 (fr)
NZ (3) NZ503234A (fr)
PL (2) PL196427B1 (fr)
PT (3) PT1019507E (fr)
SK (2) SK286495B6 (fr)
UA (2) UA73081C2 (fr)
WO (2) WO1999016876A1 (fr)
ZA (2) ZA988676B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO1999028474A2 (fr) * 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services Variants de chemokine et leurs procedes d'utilisation
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
ES2272329T3 (es) * 1999-10-25 2007-05-01 Pharis Biotec Gmbh Quimioquinina humana phc-1 procesada.
EP1167527A1 (fr) * 2000-06-22 2002-01-02 Euroscreen S.A. Chemokines humaines tronquées: PHC-1 et PHC-2
WO2001036459A2 (fr) * 1999-11-15 2001-05-25 Forssmann Wolf Georg Nouvelle utilisation de hcc-2
CA2316405A1 (fr) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation de l'inflammation a l'aide de produits du type protease
EP1176200A3 (fr) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Utilisation des polypeptides ou leurs acides nucléiques pour le diagnose ou traitement des maladies de la peau ou de la cicatrisation de blessures et leurs utilisations pour l'identification des substances pharmacologiquement actives
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
WO2003051921A1 (fr) 2001-12-17 2003-06-26 Applied Research Systems Ars Holding N.V. Mutants de chimiokines agissant en tant qu'antagonistes de chimiokines
EP1631680A2 (fr) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
CA2695237A1 (fr) 2007-08-02 2009-04-30 Novimmune S.A. Anticorps anti-rantes et leurs procedes d'utilisation
WO2011097567A1 (fr) * 2010-02-08 2011-08-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Essai multiplexé du rantes, variants du rantes se rapportant à une maladie, et variants du rantes se rapportant à une activité enzymatique
JP5975886B2 (ja) 2010-03-11 2016-08-23 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
CA3101052A1 (fr) 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Methodes d'inhibition de l'inflammation cerebrale
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01265099A (ja) 1987-10-08 1989-10-23 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
CZ290850B6 (cs) * 1994-12-08 2002-10-16 Glaxo Group Limited Polypeptid, způsob jeho výroby, kódující DNA nebo RNA, vektor a buňka
AU1532697A (en) * 1996-01-12 1997-08-01 Genetics Institute Inc. Beta-chemokine, h1305 (mcp-2)
EP0889961A2 (fr) * 1996-03-27 1999-01-13 Icos Corporation Materiels et procedes de fabrication de proteine-5 chimiotactique monocyte
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Also Published As

Publication number Publication date
EP1439231A3 (fr) 2004-12-22
DE69823218D1 (de) 2004-05-19
CN1145693C (zh) 2004-04-14
UA73080C2 (en) 2005-06-15
US6977071B2 (en) 2005-12-20
CZ299478B6 (cs) 2008-08-06
PT1439231E (pt) 2007-08-20
US20030119148A1 (en) 2003-06-26
HUP0003563A2 (hu) 2001-02-28
HUP0003505A2 (hu) 2001-02-28
NZ516027A (en) 2003-05-30
CN1233415C (zh) 2005-12-28
HK1062637A1 (en) 2004-11-19
EP1021541B1 (fr) 2004-04-14
KR20010024213A (ko) 2001-03-26
DK1019507T3 (da) 2004-07-19
NO20001584L (no) 2000-03-27
EP1439231A2 (fr) 2004-07-21
ZA988675B (en) 1999-11-24
SK286495B6 (sk) 2008-11-06
ZA988676B (en) 1999-12-03
CN1490049A (zh) 2004-04-21
KR100542934B1 (ko) 2006-01-11
CY1110927T1 (el) 2015-06-10
US7326411B2 (en) 2008-02-05
AU9747498A (en) 1999-04-23
BG64757B1 (bg) 2006-02-28
JP2001518296A (ja) 2001-10-16
US20030124677A1 (en) 2003-07-03
PT1021541E (pt) 2004-07-30
AR013528A1 (es) 2000-12-27
US6905676B2 (en) 2005-06-14
US7338653B2 (en) 2008-03-04
NZ503235A (en) 2002-08-28
PT1019507E (pt) 2004-06-30
CZ299479B6 (cs) 2008-08-06
EA200000378A1 (ru) 2000-10-30
BG64679B1 (bg) 2005-11-30
CZ20001146A3 (cs) 2000-09-13
BR9812394A (pt) 2000-09-12
AU9442098A (en) 1999-04-23
BG104267A (en) 2000-11-30
WO1999016877A1 (fr) 1999-04-08
JP2001518297A (ja) 2001-10-16
EP1019507A1 (fr) 2000-07-19
ES2287601T3 (es) 2007-12-16
ATE368742T1 (de) 2007-08-15
CA2305017A1 (fr) 1999-04-08
NO20001584D0 (no) 2000-03-27
ATE263242T1 (de) 2004-04-15
CZ20001147A3 (cs) 2000-09-13
WO1999016876A1 (fr) 1999-04-08
UA73081C2 (en) 2005-06-15
EP1439231B1 (fr) 2007-08-01
CN1148447C (zh) 2004-05-05
CA2304827A1 (fr) 1999-04-08
EP1021541A1 (fr) 2000-07-26
DE69823218T2 (de) 2004-08-26
IL135352A (en) 2006-08-20
US20050201977A1 (en) 2005-09-15
EP0905240A1 (fr) 1999-03-31
SK286439B6 (sk) 2008-10-07
HK1032426A1 (en) 2001-07-20
EA200000379A1 (ru) 2000-10-30
EA003942B1 (ru) 2003-10-30
US20050220790A1 (en) 2005-10-06
KR100560275B1 (ko) 2006-03-10
PL197569B1 (pl) 2008-04-30
HU226468B1 (en) 2008-12-29
SK4512000A3 (en) 2000-09-12
AR013529A1 (es) 2000-12-27
DE69838188D1 (de) 2007-09-13
HUP0003563A3 (en) 2005-11-28
HU226414B1 (en) 2008-11-28
DE69822856T2 (de) 2004-08-19
DK1439231T3 (da) 2007-11-05
AU750341B2 (en) 2002-07-18
KR20010024214A (ko) 2001-03-26
PL339545A1 (en) 2000-12-18
EP1019507B1 (fr) 2004-03-31
JP4230659B2 (ja) 2009-02-25
EA003940B1 (ru) 2003-10-30
US20050164936A1 (en) 2005-07-28
DE69822856D1 (de) 2004-05-06
BR9812565A (pt) 2000-08-01
PL339559A1 (en) 2000-12-18
IL135351A (en) 2006-08-20
PL196427B1 (pl) 2008-01-31
CN1271385A (zh) 2000-10-25
SK4502000A3 (en) 2000-09-12
ES2218860T3 (es) 2004-11-16
ATE264390T1 (de) 2004-04-15
ES2215324T3 (es) 2004-10-01
DK1021541T3 (da) 2004-08-02
HK1032425A1 (en) 2001-07-20
EE200000151A (et) 2001-02-15
NZ503234A (en) 2002-06-28
JP4233214B2 (ja) 2009-03-04
BG104266A (en) 2000-11-30
AU750606B2 (en) 2002-07-25
EP0905241A1 (fr) 1999-03-31
NO20001609L (no) 2000-03-28
CN1271386A (zh) 2000-10-25
NO20001609D0 (no) 2000-03-28
EP0906954A1 (fr) 1999-04-07
HUP0003505A3 (en) 2005-11-28
DE69838188T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
BR9610511B1 (pt) construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.
ATE315087T1 (de) Neuartige auf p53 ansprechende gene
BR9507678A (pt) Construção de dna vetor de expressão recombinante célula proceso para produzir uma enzima enzima preparação de enzima uso da enzima e cultura
BR9607273A (pt) Molécula de dna duplo filamento dna recombinante plasmídio célula recombinante composiçao farmacéutica e processo de preparaçao de uma molécula de dna
EE200000355A (et) IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
DE69827284D1 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
WO2004005475A3 (fr) Acides nucleiques et polypeptides d'isoforme 5 d'heparan sulfate 3-o- sulfotransferase purifies et isoles, ainsi que methodes therapeutiques et de criblage associees
FI971100L (fi) Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi
DE69737766D1 (de) Zusammensetzungen von stammzellfaktor (scf)-analogen und auf diese bezogene verfahren
ATE316138T1 (de) Rekombinante expression von s-layer-proteinen
CA2032167A1 (fr) Adn codant pour une proteine qui se lie a un activateur du gene .alpha.-fetoproteinique
MD20000034A (ro) Proteinele virusului răsucirii frunzelor de viţă de vie (tipul 2) şi utilizarea lor
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
DE69329164D1 (de) Protein mit Alpha-Glukosidase-Aktivität, DNS mit dessen genetischer Information und Herstellung von Alpha-Glukosidase
DE3584029D1 (de) Expressionsvektoren, dns-fragmente, peptide, wirte und verfahren zur herstellung von peptiden.
EP0676413A3 (fr) Protéine liant l'interféron alpha/bêta, sa production et son application.
BR9606521A (pt) Polinucleotídeo purificado e isolado molécula de dna construção de expressão de dna célula hospedeira método para produzir um polipeptídeo humano polipeptídeo purificado e isolado anticorpo e linhagem celular de hibridoma
BR9508430A (pt) Sequência nucleotídica ADN recombinante vetor de expressão com replicação autônoma e/ou integrativo célula recombinante polipeptideo processo de produção de um polipeptideo topoismorase isolada e utilização de uma topoisomeras IV

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner